Emyria
Emyria operates a network of specialist medical clinics focused on collecting and commercializing clinical data. The company leverages proprietary software to gather anonymized patient data, which is then used to generate clinical evidence. This positions Emyria uniquely in the healthcare sector, combining medical services with data-driven insights.
Short position
Emyria (ASX:EMD) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 6,369 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.10% in February 2020. EMD is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Emyria (EMD) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXAppendix 4G and Corporate Governance Statement
other announcement
Letter to Shareholders - Notice of Annual General Meeting
other announcement
Notice of Annual General Meeting/Proxy Form
other announcement
Retirement of Non-Executive Director
other announcement
Webinar with Former Secretary of Veterans Affairs Dr Shulkin
other announcement
Notification of cessation of securities - EMD
other announcement
Emyria Successfully Opens First NSW Empax Clinic
other announcement
KalkineWhich clinics will drive Emyria (ASX:EMD) psychedelic growth?
Highlights Emyria has grown its Empax network of psychedelic-assisted therapy clinics across several states within a single financial year. Its Perth clinic has reached profitability at the site level, offering a template for newer locations still ramping up. A TGA change broadening eligible therapists could ease a key workforce bottleneck as a New South Wales site prepares to open. Emyria (ASX:EMD) used its full-year results presentation earlier this month to show how quickly its psychedelic...
What Does Emyria’s (ASX:EMD) New Share Quotation Mean?
Highlights Emyria has applied for ASX quotation of additional fully paid ordinary shares. The new securities arise from the exercise or conversion of existing securities. The development adds to Emyrias quoted capital structure as the company continues its mental health care and drug-development activities. Emyria Limited (ASX:EMD) has applied for quotation of additional ordinary shares on the ASX, providing an update on the companys listed securities. The healthcare company operates across me...
Application for quotation of securities - EMD
other announcement
StockheadEmyria taps former US Veterans Affairs chief for US healthcare push
Dr Shulkin is a physician, healthcare executive and former US Cabinet Secretary who has worked across federal healthcare, veterans’ health, ... Read More The post Emyria taps former US Veterans Affairs chief for US healthcare push appeared first on Stockhead.
Former US Veterans Affairs Secretary Joins Emyria
other announcement
Emyria Presentation at FDA Hearing
other announcement
Which Clinics Are Powering Emyria (ASX:EMD) Revenue Growth?
Highlights Full-year results showed revenue multiplying as the psychedelic-assisted therapy clinic network expanded nationally. [ASX 300] The trained clinical workforce and pool of authorised prescribers both grew substantially over the period. A new site in New South Wales extends the network across Australia's largest states. Emyria, the Western Australian clinical services company trading as (ASX:EMD), presented full-year results in early September showing revenue multiplying as its networ...
Emyria selected for limited speaking spot at US FDA hearing
The ‘Considerations for Potential Future Therapeutic Use of Psychedelic Drugs’ hearing will be held at the FDA’s White Oak Campus ... Read More The post Emyria selected for limited speaking spot at US FDA hearing appeared first on Stockhead.
What Does Emyria (ASX:EMD) Clinic Rollout Signal Now?
Highlights Full-year revenue climbed sharply as the treatment network expanded nationally. The original Perth clinic reached break-even at the site level. Group losses persisted while newer clinics worked toward steady utilisation. Emyria (ASX:EMD) has walked the market through a full-year result in which revenue roughly tripled and its treatment network expanded from a single clinic to a multi-site national footprint. The Western Australian company delivers supervised psychedelic-assisted th...
Emyria’s first Sydney Empax clinic on track for September opening
EMD delivers regulated mental health treatments through its clinical services and has recruited and trained ~20 Sydney-based therapists and four ... Read More The post Emyria’s first Sydney Empax clinic on track for September opening appeared first on Stockhead.
FDA Selects EMD to Present at Psychedelic Medicines Hearing
other announcement
Small CapsEmyria Prepares First Sydney Clinic for September Launch
Emyria to open Sydney clinic in Sept 2026, expanding NSW reach; 20 therapists, 4 psychiatrists (2 authorised prescribers) ready; patients approved.
Emyria Set to Launch First NSW Clinic
other announcement
Emyria Year End Presentation for Investor Webinar
other announcement
Emyria Financial Year-end Update Webinar
other announcement
Emyria recruits 15 therapists to expand Empax clinic capacity
Emyria said therapist availability was now the next capacity lever. It has moved to address that constraint, with 15 new ... Read More The post Emyria recruits 15 therapists to expand Empax clinic capacity appeared first on Stockhead.
Appendix 4E & Annual Financial Report Year End 30 June 2026
other announcement
2026 Annual General Meeting - Key Dates
other announcement
Why Is Emyria (ASX:EMD) Back in Cannabis Focus?
Highlights The clinical group has cleared a prescriber capacity bottleneck across its Western Australian and Queensland treatment sites. Newly recruited therapists largely meet revised regulator eligibility criteria, allowing additional dosing days to be scheduled. A fifth treatment clinic extends the network into New South Wales, giving national coverage across major states. A shift in sector emphasis is giving the latest update from Emyria (ASX:EMD) more context than the headline alone conv...
Change of Registered Office and Principal Place of Business
other announcement
Emyria expands Empax clinic network in milestone June quarter
EMD continues to scale its Empax clinic network under a capital-light, hospital-integrated model, with operations spanning multiple Australian states. ... Read More The post Emyria expands Empax clinic network in milestone June quarter appeared first on Stockhead.
What Is Putting Emyria (ASX:EMD) in Focus?
Highlights Emyria reports sharply higher half-year revenue as patient numbers grow across its Emerald Clinics network. The company completes staff training ahead of opening a further specialist clinic focused on mental health and neurological conditions. Real-world patient data collected across the clinic network continues to feed the group's broader drug development pipeline. Emyria (ASX:EMD), the Perth-headquartered drug development company that also owns and operates the Emerald Clinics ne...
June 2026 Quarterly Activities Report and Appendix 4C
other announcement
Why Is Emyria (ASX:EMD) Facing a Proof-First Market?
Highlights Australias cannabis sector is increasingly rewarding demonstrated commercial and clinical progress rather than ambitious narratives. Cost discipline and funding resilience now carry greater weight as companies manage capital-intensive operations. Revenue, prescriptions, product availability and clinical evidence have become the proof points separating stronger operators from weaker stories. Australias cannabis sector is entering a more demanding phase, and Emyria (ASX:EMD) sits...
EMD to Present at Addressing the Mental Health Crisis Event
other announcement
Emyria to Present at Upcoming Investor and Industry Events
other announcement
Top ASX Cannabis Stock to Watch: Can Emyria (ASX:EMD) Stay Ahead as Rules Tighten?
Highlights Regulatory scrutiny is reshaping Australia's medicinal cannabis industry with stronger compliance requirements. Telehealth prescribing models are facing closer oversight as authorities tighten enforcement. Evidence-driven operators could gain an edge as compliance standards rise across the sector. Australia's medicinal cannabis sector is entering a defining phase as tighter regulatory oversight reshapes how businesses operate across the market. While sentiment in the broader Au...
Top Reasons Emyria (ASX:EMD) Is Expanding Beyond Cannabis Into Psychedelic Care
Highlights Emyria has secured a supply of clinical-grade MDMA to support supervised psychedelic-assisted therapy for a sizeable patient cohort. Australia's early regulatory framework for psychedelic medicines is helping the company build a clinically focused treatment model. The expansion strengthens Emyria's position within the ASX Cannabis Stocks category while broadening its healthcare offering. Australia's share market is ending the week against a backd...
Google NewsHere's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation - simplywall.st
Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation simplywall.st
Early depression program data puts Emyria on conference stage
Emyria is presenting early findings from the first cohort in its depression program at this week's International Mental Health Conference ... Read More The post Early depression program data puts Emyria on conference stage appeared first on Stockhead.
Emyria Depression Program Shows Positive Results
other announcement
Emyria trains NSW workforce ahead of Sydney Empax clinic opening
Emyria finalises training for the first cohort of Sydney therapists ahead of a planned Q3 CY26 opening of its first ... Read More The post Emyria trains NSW workforce ahead of Sydney Empax clinic opening appeared first on Stockhead.
Emyria Confirms NSW Workforce Ahead of Clinic Opening
other announcement
Change of Director's Interest Notice x 2
director_dealing announcement
TGA Update to Accelerate Empax Therapist Recruitment
other announcement
Emyria expands Empax network into NSW as clinic rollout progresses
Emyria has reported March quarter progress across its expanding Empax clinic network, alongside a new partnership to establish a clinic ... Read More The post Emyria expands Empax network into NSW as clinic rollout progresses appeared first on Stockhead.
Emyria Extends National Expansion into New South Wales
other announcement
March 2026 Quarterly Activities Report and Appendix 4C
other announcement